EGFR and cancer: In recent decades, molecular targeted therapy has demonstrated clinical efficacy in cancer patients, such as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) for advanced NSCLC patients with EGFR mutations.